Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose Response Evaluation of SLIToneULTRA HDM Mix Immunotherapy
2012-002177-62Phase 2Completed
- Sponsor
- ALK-Abelló
- Start
- Aug 2012
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2 trial of SLIToneULTRA HDM Mix in allergic rhinitis (AR) (3 arms), sponsored by ALK-Abelló. Primary endpoint: Change in specific IgE-blocking factor to Dermatophagoides pteronyssinus. Started Aug 2012; status: completed.
02
Drugs
SLIToneULTRA HDM Mix
03
Conditions
allergic rhinitis (AR)
Beyond the preview
Go deeper on 2012-002177-62.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-002177-62.